Drug Controller Approves 2 Vaccines and Merck’s Anti-viral Drug for EU
- Centre on Tuesday announced the approval through Twitter.
- Corbevax, Covovax and Molnupiravir, are granted EU authorization.
- So far centre has supplied more than 149.06 crore vaccine doses to States and UTs
New Delhi: The Centre on Tuesday approved two more vaccines and one anti-viral drug for Emergency use. The health minister taking to his Twitter handle confirmed the approval of Corbevax and Covovax along with Molnupiravir.
In his tweet, Health Minister Mansukh Mandaviya appreciated the efforts by the scientists during the pandemic.Part of his tweet read- “It’s a hat-trick! Its now third vaccine developed in India.” Corbevax, is India’s maiden “RBD protein sub-unit vaccine being manufactured by Hyderabad based pharmaceutical, Biological-E.
Molnupiravir, will be manufactured in the country by 13 pharma brands. The anti-viral drug prescribed for adultadministration is advised when SpO2 is 93% and/or the adult is having high risk of progression of diseases. Covovax will be produced by SII Pune, the health ministry added.
Since the inception of the national vaccination drive, the govt has supplied 1,49,06,76,985 doses to the states and the UTS through direct procurement category and free of cost channel. As per the data given in by the state health bulletin’s, more than 16.80 crore unutilized vaccine doses are available.++